Melanoma Clinical Trials

The RAH Cancer Clinical Trials Unit is the largest melanoma unit in SA. It offers clinical trials that address the needs of patients with all stages of melanoma. Some of these treatments are promising and may well improve outcomes for South Australian melanoma patients. The current clinical trials offered are:

Adjuvant Treatment

CA209-401: Clinical Trial of Nivolumab (BMS-936558) Combined with Ipilimumab followed by Nivolumab Monotherapy as First –Line therapy of subjects with histologically confirmed Stage III (Unresectable) or /Stage IV Melanoma

EORTC Keynote 29: Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group

Metastatic Disease

ABC: A Phase II study of nivolumab combined with ipilimumab in patients with melanoma brain metastases.

CARPETS: a Phase I parallel group study of the safety and immune effects of an escalating dose of autologous GD2 chimeric antigen receptor expressing peripheral blood T cells in patients with GD2-positive metastatic melanoma.

If you wish to donate money for research sponsored by Melanoma SA or to make a bequest, please enquire at:

RAH Research Fund (Attention Mr. Mark Goldsmith)

Sheridan Building
North Terrace
Adelaide SA 5000
Phone: (08) 8222 5281
Fax: (08) 8222 5932

For further Information

1. Australia and New Zealand Melanoma Trials Group
External Link

2. Australian Clinical Trials
External Link

3. Cancer Australia
External Link

4. National Comprehensive Cancer Network Recent Updates to NCCN clinical practise guidelines in Oncology TM Melanoma version 1.2010
External Link (needs log in or register)

5. NHMRC Clinical practice guidelines for the management of Melanoma in Australia and New Zealand (2008)

6.Melanoma Institute Australia
External Link

7. Melanoma patients Australia
External Link